Navigation Links
Study finds warfarin underutilized in women

LEXINGTON, Ky. (Dec. 13, 2011) Dr. Rabab Mohsin, an internal medicine resident at the University of Kentucky, working with Dr. Alison Bailey of the University of Kentucky Gill Heart Institute, has discovered that the drug warfarin was underutilized in a large study group of women.

Working in conjunction with the Kentucky Women's Health Registry, Mohsin, Bailey and fellow investigators identified women who reported arrhythmia (irregular heartbeat) identification and treatment. Specifically, the investigators worked to determine whether prescription warfarin (an anti-coagulant known as a safe and effective treatment for atrial fibrillation) was being appropriately utilized among a population of Kentucky women with self-reported atrial fibrillation.

Survey data revealed that among the group of women who would be expected to be receiving warfarin, only 30 percent were receiving the drug. Notably, the research population was found to have a higher than average level of income and education as compared to other Kentucky women in their age group. Statistical analysis also revealed that older women were more likely to be taking warfarin (a mean age of 73.4 years was found for those with atrial fibrillation who were on warfarin, while the population with atrial fibrillation but without warfarin treatment had a mean age of 61.8).

Overall, Mohsin, Bailey and fellow investigators concluded that warfarin anticoagulation treatment for atrial fibrillation is underutilized in the group of Kentucky women studied, and that this underutilization is not attributable to economic or educational disparities.


Contact: Allison Elliott
University of Kentucky

Page: 1

Related medicine news :

1. RI Hospital receives $1.5 million grant to study treatments for body dysmorphic disorder
2. Study explores mens ability to manage fear in ways that allow them to exhibit confidence
3. JDRF-funded study seeks to reduce cardiovascular risk
4. Study Questions Use of MRI Before Back-Pain Injections
5. ADHD Drugs Dont Raise Risk of Heart Problems: Study
6. Snakes Make Your Skin Crawl? Study Suggests Why
7. Study of 2 sisters sheds light on lymphoma evolution
8. Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal
9. Patient isolation associated with hospital delirium: study
10. Ruxolinitib better at reducing myelofibrosis symptoms, study shows
11. Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma
Post Your Comments:
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... It’s ... has a tattoo — a number even greater among Millennials (a whopping one in ... are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
(Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
Breaking Medicine Technology: